PE/Cyanine7 anti-human IL-10 Antibody

Pricing & Availability
Clone
JES3-9D7 (See other available formats)
Regulatory Status
RUO
Other Names
Interleukin-10, B cell derived T cell growth factor (B-TCGF), Cytokine synthesis inhibitory factor (CSIF), T-cell growth inhibitory factor (TGIF)
Isotype
Rat IgG1, κ
JES3-9D7_PECyanine7_IL-10_Antibody_1_111424
LPS-stimulated (overnight) human peripheral blood mononuclear cells surface stained with CD14 APC and intracellularly stained with IL-10 (clone JES3-9D7) PE/Cyanine7 (left) or rat IgG1 isotype control PE/Cyanine7 (right) (gated on monocyte population)
  • JES3-9D7_PECyanine7_IL-10_Antibody_1_111424
    LPS-stimulated (overnight) human peripheral blood mononuclear cells surface stained with CD14 APC and intracellularly stained with IL-10 (clone JES3-9D7) PE/Cyanine7 (left) or rat IgG1 isotype control PE/Cyanine7 (right) (gated on monocyte population)
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability
501419 25 tests $147.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
501420 100 tests $347.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production.

Technical data sheet

Product Details

Verified Reactivity
Human
Reported Reactivity
Baboon, Rhesus, Cynomolgus
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
COS - expressed, recombinant human IL-10
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA Capture1-5 or ELISPOT Capture6: The Ultra-LEAFpurified JES3-9D7 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated JES3-12G8 antibody (Cat. No. 501502) as the detecting antibody and recombinant human IL-10 (Cat. No. 571009) as the standard. The Ultra-LEAF™ purified antibody is suggested for ELISPOT capture.
Neutralization1-3,9: The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IL-10 bioactivity (Cat. Nos. 501427 & 501428). The JES3-9D7 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Additional reported applications (for the relevant formats) include: immunohistochemical staining12.
Note: For testing human IL-10 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. Nos. 430601 & 430606) are specially developed and recommended.

The JES3-9D7 antibody reacts with human and viral interleukin-10 (IL-10).

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA Capture, Neut)
  2. Gotlieb W, et al. 1992. Cytokine 4:385. (ELISA Capture, Neut)
  3. Yssel H, et al. 1992. J. Immunol. 149:2378. (ELISA Capture, Neut)
  4. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA Capture)
  5. Burdin N, et al. 1993. J. Exp. Med. 177:295. (ELISA Capture)
  6. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISPOT Capture)
  7. Schaerli P, et al. 2000. J. Exp. Med. 192:1553.
  8. Jason J, et al. 1999. Clin. Diagn. Lab Immunol. 6:73.
  9. Akdis CA, et al. 1998. J. Clin. Invest. 102:98. (Neut)
  10. Stary G, et al. 2011. J. Immunol. 186:103. PubMed
  11. Mason GM, et al. 2012. PNAS. PubMed
  12. 12. Smith DR, et al. 1994. Am. J. Pathol. 145:18. (IHC)
Product Citations
  1. Zhang M, et al. 2023. JCI Insight. 8: . PubMed
  2. Lee HS, et al. 2023. Biol Pharm Bull. 46:542. PubMed
  3. Solforosi L, et al. 2023. Nat Commun. 14:1944. PubMed
  4. Boer M, et al. 2015. Clin Vaccine Immunol. 22: 778 - 788. PubMed
  5. Alenazy MF, et al. 2021. Sci Rep. 11:5629. PubMed
  6. James E, et al. 2016. PLoS Pathog. 12: 1005375. PubMed
  7. Woolsey C, et al. 2020. Scientific Reports. 10(1):3071.. PubMed
  8. Meng Y,et al. 2017. Cell Death Dis. . 10.1038/cddis.2017.505. PubMed
  9. Khanolkar R, et al. 2016. J Leukoc Biol. 100: 737 - 746. PubMed
  10. Shen X, et al. 2021. Front Immunol. 12:710750. PubMed
  11. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  12. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  13. Masson A, et al. 2015. Blood. 125:1830. PubMed
  14. Tai YT, et al. 2019. Leukemia. 33:426. PubMed
  15. Rascle P, et al. 2021. iScience. 24:103109. PubMed
  16. Anang DC, et al. 2022. Cells. 11:. PubMed
  17. Salvany‐Celades M et al. 2019. Cell Rep. 27(9):2537-2547 . PubMed
  18. Glaser K, et al. 2016. PLoS One. 11: 0146898. PubMed
  19. Levin MJ, et al. 2018. J Clin Invest. 128:4429. PubMed
  20. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  21. Csomós K, et al. 2022. Nat Immunol. 23:1256. PubMed
  22. Lu H, et al. 2020. Am J Reprod Immunol. 83:. PubMed
  23. Tesch S, et al. 2020. Sci Rep. 10:21312. PubMed
RRID
AB_2125385 (BioLegend Cat. No. 501419)
AB_2125385 (BioLegend Cat. No. 501420)

Antigen Details

Structure
Acid-labile cytokine, dimer, 35-40 kD (Mammalian)
Bioactivity
Inhibit IFN-γ, TNF-β, IL-2 production by TH1 clones; inhibits macrophage-mediated IL-1, IL-6, TNF-α synthesis; suppress delayed type hypersensitivity response; stimulate TH2 cell response; mast cell proliferation in
Cell Sources
Activated CD8+ and CD4+ T cells, activated monocytes, mast cells, Ly-1 B (mouse)
Cell Targets
T cells, B cells, mast cells, macrophages
Receptors
IL-10R (CDw210)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. de Waal-Malefyt R, et al. 1992. Curr. Opin. Immunol. 4:314.
3. Howard M, et al. 1992. Immunol. Today. 13:198.
4. Quesniaux V. 1992. Research Immunol. 143:385.

Regulation
Production inhibited by IL-4, IL-10
Gene ID
3586 View all products for this Gene ID
UniProt
View information about IL-10 on UniProt.org
Go To Top Version: 3    Revision Date: 06/28/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account